Salarius Pharmaceuticals (Salarius Pharmaceuticals) 6-Month Price Index : 0.70 (As of Jun. 06, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Salarius Pharmaceuticals 6-Month Price Index?

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2024-06-06), Salarius Pharmaceuticals's 6-Month Price Index is 0.70.

Competitive Comparison of Salarius Pharmaceuticals's 6-Month Price Index

For the Biotechnology subindustry, Salarius Pharmaceuticals's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Salarius Pharmaceuticals (NAS:SLRX) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index

Current Share Price

Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Salarius Pharmaceuticals (NAS:SLRX) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Salarius Pharmaceuticals 6-Month Price Index Related Terms

Thank you for viewing the detailed overview of Salarius Pharmaceuticals's 6-Month Price Index provided by GuruFocus.com. Please click on the following links to see related term pages.

Salarius Pharmaceuticals (Salarius Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Salarius Pharmaceuticals Inc (NAS:SLRX) » Definitions » 6-Month Price Index

Comparable Companies

Traded in Other Exchanges

FP1:Germany

Address

2450 Holcombe Boulevard, Suite X, Houston, TX, USA, 77021

Website

https://www.salariuspharma.com

Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The Company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.

Executives

Tess Burleson	director	2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Jonathan I Lieber	director	C/O HISTOGENICS CORPORATION, 830 WINTER STREET #3, WALTHAM MA 02451
William K. Mcvicar	director	C/O INOTEK PHARMACEUTICALS CORPORATION, 131 HARTWELL AVENUE, SUITE 105, LEXINGTON MA 02421
Arnold C Hanish	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Mark J Rosenblum	officer: Exec VP Finance, Interim CFO	3990 SPRING VALLEY ROAD, APT. 1218, DALLAS TX 75244
David J. Arthur	director, officer: Chief Executive Officer	2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Scott Jordan	officer: Chief Financial Officer	2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Mccreedy Bruce J Jr.	director	2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Jonathan P Northrup	director	2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Pao-yu Chuang	officer: Controller	2450 HOLCOMBE BLVD., SUITE J-608, HOUSTON TX 77021
Paul Lammers	director	2408 TIMBERLOCH PLACE, B-7, THE WOODLANDS TX 77380
Boston Foundation, Inc.	10 percent owner	75 ARLINGTON STREET, BOSTON MA 02116
Christoph H Westphal	10 percent owner	C/O ALNYLAM PHARMACEUTICALS, INC, 300 THIRD STREET, CAMBRIDGE MA 02142
Longwood Fund Ii, L.p.	10 percent owner	800 BOYLSTON STREET, SUITE 1555, BOSTON MA 02199
Roger D Tung	director	99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421